H.R. 6348 · 114th Congress
To extend for two years the program for priority review to encourage treatments for rare pediatric diseases.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
GraysonSponsorNo cosponsors.
This bill amends the Federal Food, Drug, and Cosmetic Act to extend through 2018 the priority review voucher program for treatments for rare pediatric diseases. (A priority review voucher is a transferable voucher that entitles the holder to have a new drug or biological product application acted upon by the Food and Drug Administration within six months.)
What it does: CRS summary · Introduced in House · Nov 17, 2016
This bill amends the Federal Food, Drug, and Cosmetic Act to extend through 2018 the priority review voucher program for treatments for rare pediatric diseases. (A priority review voucher is a transferable voucher that entitles the holder to have a new drug or biological product application acted upon by the Food and Drug Administration within six months.)
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: To extend for two years the program for priority review to encourage treatments for rare pediatric diseases.
Latest action (Nov 17, 2016): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Nov 17, 2016
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.